Biotechnology and Pharmaceuticals

March 20, 2020

Buy ($175)

Companies covered: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), Allogene Therapeutics (NASDAQ:ALLO), CRISPR Therapeutics AG (NASDAQ:CRSP), Precision BioSciences (NASDAQ:DTIL), Celyad SA (ADR) (NASDAQ:CYAD), Cellectis S.A. (NASDAQ:CLLS), Pfizer, Inc. (NYSE:PFE), Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Selecta Biosciences Inc (NASDAQ:SELB), Horizon Pharma plc (NASDAQ:HZNP), Calyxt (NASDAQ:CLXT), Amgen Inc. (NASDAQ:AMGN), Novartis AG (NYSE:NVS), Allergan, Inc. (NYSE:AGN), AbbVie Inc. (NYSE:ABBV), Bristol-Myers Squibb Company (NYSE:BMY), H. Lundbeck A/S (ADR) (OTCMKTS:HLUYY), Karuna Therapeutics (NASDAQ:KRTX), Satsuma Pharmaceuticals (NASDAQ:STSA), BioLife Solutions, Inc. (NASDAQ:BLFS), Brooks Automation, Inc. (NASDAQ:BRKS), Catalent, Inc. (NYSE:CTLT), CryoPort Inc. (NASDAQ:CYRX), Repligen Corporation (NASDAQ:RGEN), Bio-Techne Corp (NASDAQ:TECH), Biogen Inc. (NASDAQ:BIIB), Denali Therapeutics (NASDAQ:DNLI), Amicus Therapeutics, Inc. (NASDAQ:FOLD), WuXi Biologics Cayman (OTCMKTS:WXIBF), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Rocket Pharmaceuticals (NASDAQ:RCKT), Novocure Ltd. (NASDAQ:NVCR), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Moderna (NASDAQ:MRNA), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), SCYNEXIS, Inc. (NASDAQ:SCYX), Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Omeros Corporation (NASDAQ:OMER), Medicenna Therapeutics Corp. (NASDAQ:MDNA), Veru Inc. (NASDAQ:VERU), Chiasma (NASDAQ:CHMA), Atreca Inc. (NASDAQ:BCEL), Monopar Therapeutics (NASDAQ:MNPR), Vaxart (NASDAQ:VXRT), CEL-SCI Corporation (NYSEAMERICAN:CVM), ProMIS Neurosciences (TSE:PMN), Fortress Biotech, Inc. (NASDAQ:FBIO), Achieve Life Sciences (NASDAQ:ACHV), AzurRx BioPharma (NASDAQ:AZRX), Passage Bio (NASDAQ:PASG), Pressure BioSciences Inc. (OTCMKTS:PBIO), Sensus Healthcare (NASDAQ:SRTS), Nanobiotix (EPA:NANO), Protagonist Therapeutics, Inc. (NASDAQ:PTGX), Quick-Med Technologies Inc. (OTCMKTS:QMDT), RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI), Mesoblast Limited (NASDAQ:MESO), Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)